Type 2 diabetes mellitus (T2DM) is a major cause of morbidity in the Middle East; however, Arab populations remain underrepresented in genomic studies. We synthesized evidence on single-nucleotide polymorphisms (SNPs) associated with T2DM risk in Egyptian and Levant (Jordan, Lebanon, Palestine, and Syria) cohorts to identify shared and population-specific loci. We conducted a PRISMA-aligned systematic review and meta-analysis (PROSPERO CRD420251162068) of case–control genetic studies published until July 2025. Eligible studies enrolled ≥ 60 participants, reported odds ratios (ORs) with 95% confidence intervals (CIs), and satisfied the Hardy–Weinberg equilibrium in controls. Pooled effects used fixed- and random-effects models according to heterogeneity (Cochran’s Q, I², and τ²). Publication bias was assessed using Egger’s and Begg’s tests and funnel plot symmetries. Sensitivity analyses included leave-one-out procedures and meta-regression using study-level moderators (case/control counts). Exploratory clustering and random forest models were used to examine gene/SNP features related to effect size. In Egyptians (45 SNPs), between-study heterogeneity was negligible (Q = 35.32, df = 43, p = 0.79; I² = 0%; τ² = 0). Strong risk associations were observed for IGFB rs2854843 (OR = 13.30, p = 0.001), MTHFR rs1801133 (OR = 4.60, p = 0.001), GCKR rs780094 (OR = 3.99, p = 0.001), and TCF7L2 rs12255372 (OR = 2.06, p = 0.0001); additional signals were observed for ADIPOQ and KCNJ11. Egger’s test suggested minor small-study effects (p = 0.0184), whereas Begg’s test did not (p = 0.721). Meta-regression indicated that larger case counts and smaller control counts were associated with inflated ORs (R² ≈ 0.15). In the Levant cohort (29 SNPs), heterogeneity was high (Q = 302.32, df = 28, p < 0.0001; I² = 90.7%). Notable loci included NAT2 rs1799931 (OR = 13.72, p = 0.043) and SH2B1 rs565131715 (OR = 7.55), with lower magnitude associations for ADIPOQ and KCNQ1. No significant publication bias was detected. Egyptian findings revealed consistent large-effect SNP associations with T2DM, whereas Levant populations showed variable context-dependent effects. Shared markers (TCF7L2, ADIPOQ, and KCNJ11) and population-specific candidates (IGFB, NAT2, and SH2B1) may inform targeted screening and risk stratification. Harmonized, adequately powered multicenter studies are needed to validate these findings and accelerate precision medicine in underrepresented Arab populations.
Musafer et al. (Tue,) studied this question.